Objectives: To determine the population structure and change in drug resistance of pneumococci colonizing children before and after the introduction of the 10-valent and 13-valent pneumococcal conjugate vaccines (PCV10/13) in Brazil.
Introduction
The universal use of pneumococcal conjugate vaccines (PCVs) has been continuously changing the pneumococcal population ecology in the human nasopharynx, which constitutes the major reservoir of Streptococcus pneumoniae.
1 High PCV coverage in a given population has been followed by a notable decrease in the prevalence of carriage and invasive pneumococcal diseases (IPDs) with vaccine serotypes. Subsequently, non-vaccine serotypes and non-encapsulated S. pneumoniae have emerged in both colonization and IPDs, a phenomenon termed serotype replacement. 2 In Brazil, the 10-valent PCV (PCV10) and the 13-valent PCV (PCV13) were introduced in 2010. Since then, PCV10 has been provided free as part of the public childhood National Immunization Program and, by 2013, nationwide PCV10 vaccination coverage had reached over 90% in the eligible population (children 2 months old). 3 In turn, PCV13 replaced the 7-valent PCV (PCV7) in private health clinics with immunization services. Nevertheless, only a small portion of the population has been vaccinated with either PCV7 or PCV13 owing to their high costs. A previous study conducted in 2014 in south-eastern Brazil showed that only 8% of eligible children had received at least one dose of PCV13 in contrast to the 86% that had received PCV10. 4 V C The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Despite the high coverage (86%) of PCV10 in this region, the proportion of penicillin-non-susceptible pneumococci (PNSP) associated with carriage among children under 6 years old was high before (27%) and after (39%) 4 years of routine vaccination. Additionally, frequencies of non-susceptibility to erythromycin, clindamycin and tetracycline were at least 20% higher when compared with the pre-PCV10 period, mostly because of the emergence of MDR serotype 6C isolates. 4, 5 The effects of PCVs are dependent on serotype distribution and clonal structure of the pneumococcal population. Each serotype, however, may be comprised of multiple lineages with various antimicrobial resistance patterns and different potential for causing IPDs. 6 Here, by genotyping pneumococcal isolates, we investigated the impact of PCVs on the population structure of pneumococcal strains carried by children before and after universal pneumococcal conjugate vaccination in Brazil, focusing on changes in serotype distribution and drug resistance prevalence.
Materials and methods

Ethics
The Ethics Committee at the Universidade Federal Fluminense School of Medicine approved this study (CAAE no. 0142.0.258.000-09 and 26823614.2.0000.5243). Written, informed consent was obtained from the parents or legal guardians of all participants.
Pneumococcal isolates
Methods for specimen collection and processing were previously described in detail. 4, 5 Two hundred and fifty-six pneumococcal isolates recovered from the nasopharynx of children ,6 years of age were included in the study. Samples were obtained from seven institutions distributed across five different neighbourhoods in Niterói city, Rio de Janeiro state, Brazil, with driving distances between them ranging from 0.4 km to 9.0 km. Table S1 (available as Supplementary data at JAC Online) describes the source, date of isolation, serotypes, STs and antimicrobial susceptibility patterns of the isolates.
Between December 2009 and August 2010 (pre-PCV10/13 period), we recovered 125 isolates from 123 (47.1%) of 261 children recruited at two public hospitals and two public childcare centres (CCCs) in the city of Niterói, where citywide PCV10 vaccination began in October 2010. Children at the public hospitals were mostly symptomatic (91.8%; 134/146) with respiratory or general symptoms, whereas the proportion of healthy (n " 65; 56.5%) and symptomatic (n " 50; 43.5%) children at the CCCs was more balanced.
Between September and December 2014 (post-PCV10/13 period), we recruited 573 children who attended one public clinic or two private paediatric clinics for routine check-up (333; 58.1%) or sick (240; 41.9%) visits and recovered 131 (22.9%) isolates. In the post-PCV10/13 period, only three children were ineligible for PCV (aged ,2 months). Data on vaccination status were not available for four additional children (all aged 3-5 years). Capsular types were determined by sequential multiplex PCR (https:// www.cdc.gov/streplab/downloads/pcr-latin-amer-clinical-specimens.pdf), cpsB sequencing with modifications 4 and/or Quellung reaction. Isolates from the pre-PCV10/13 period were characterized by sequential multiplex PCR and Quellung reaction. Isolates from the post-PCV10/13 period were initially characterized by sequential multiplex PCR; those not resolved by PCR were subjected to cpsB sequencing and all serogroup 6 isolates were typed by Quellung reaction (Table S1 ).
Using the disc diffusion method, we evaluated the isolates for antimicrobial susceptibility to chloramphenicol, clindamycin, erythromycin, levofloxacin, penicillin (with oxacillin discs), rifampicin, sulfamethoxazole/ trimethoprim, tetracycline and vancomycin. MICs of ceftriaxone, penicillin and erythromycin were determined by Etest V R (bioMérieux, Marcy l'Etoile, France). CLSI interpretative criteria were applied. 7 Strains showing penicillin MICs 0.12 mg/L were classified as PNSP. MDR isolates were defined as those that were non-susceptible (intermediate or resistant) to at least one drug from three or more different classes of antimicrobial agents. Apart from penicillin and ceftriaxone, which are both b-lactams, all drugs tested belong to different classes, as follows: fluoroquinolones (levofloxacin), glycopeptides (vancomycin), lincosamides (clindamycin), macrolides (erythromycin), phenicols (chloramphenicol), rifamycins (rifampicin), sulphonamides/diaminopyrimidines (sulfamethoxazole/trimethoprim) and tetracyclines (tetracycline).
MLST
DNA from pneumococcal isolates was obtained by boiling a loopful (10 lL loop) of an overnight culture in 300 lL of water or with the Chelex V R 100 resin (Bio-Rad, Hercules, CA, USA). 8 MLST of isolates from pre-and post-PCV10/ 13 periods was performed at the Streptococcus Laboratory (CDC, Atlanta, GA, USA) and the School of Public Health (University of California, Berkeley, CA, USA), respectively, as described elsewhere, 9 with modified primers (http://www.cdc.gov/streplab/alt-MLST-primers.html/). Alleles and STs were assigned according to the MLST website (http://pubmlst.org/spneumo niae/), where new alleles and STs were also deposited. Minimum spanning trees were constructed to predict clonal complexes (CCs) with BioNumerics v7.6 (Applied Maths, Ghent, East Flanders, Belgium). STs sharing five [double-locus variants (DLVs)] or six [single-locus variants (SLVs)] identical alleles were included in the same CC, named after the predominant ST in the group. STs not assigned to any CC were designated singletons. We confirmed the occurrence of serotype switching events when isolates sharing the same ST belonged to different serotypes.
Statistical analyses
We used the v 2 test to compare characteristics of the isolates by sampling period, with level of significance of ,0.05. We determined P values using two-tailed differences at 95% CI. We calculated the Simpson's diversity index (SDI) with 95% CI to measure the genetic diversity by MLST.
10,11
Results MLST revealed 97 different STs among the 256 isolates, including 36 new STs. Thirty-three STs were only found in the pre-PCV10/13 period, 47 only in the post-PCV10/13 period and 17 in both periods ( Figure 1 ). The most frequent STs (found at least four times) are listed in Table 1 , along with their associated serotype.
In the pre-PCV10/13 period, there were 14 (11%) serotype 6B-ST724, 10 (8%) serotype 14/NT-ST156, 9 (7%) serotype 17F-ST739 and 6 each (5%) of serotype 23F-ST338, serotype 15C-ST766 and 15C-ST1262 isolates ( Figure 1a ). In the post-PCV10/13 period, there were 14 (11%) serotype 6C-ST386, 9 (7%) capsular type 11A/D-ST62 and 6 (5%) each of capsular type 23A-ST42, 15B/ C-ST766 and 15B/C-ST1262 isolates (Figure 1b) .
Among the 125 isolates from the pre-PCV10/13 period, we observed 50 different STs, distributed into eight CCs and 28 singletons. CC724 was the most common CC, comprising 22 (17.6%) isolates ( Figure 1a ). Nineteen STs were described for the first time, of which 12 were novel combinations of previously described alleles and seven were composed of eight new alleles of the gki (316), recP (193), spi (293, 298, 303) and/or ddl (477, 480, 490) genes.
In the post-PCV10/13 era, we detected 64 different STs among the 131 isolates, distributed into 12 CCs and 27 singletons. CC386
Post-vaccination emergence of the MDR serotype 6C-CC386 in Brazil JAC was the most common CC with 15 (11.5%) isolates (Figure 1b) . Seventeen new STs were described; nine were novel combinations of previously described alleles and eight were composed of eight new alleles of the gdh (477), spi (481), xpt (647, 648, 649, 650) or ddl (697, 698) genes. High indices of diversity were observed in both periods, with SDIs of 0.966 (95% CI 0.954-0.978) and 0.974 (95% CI 0.964-0.985) in the pre-and post-PCV10/13 periods, respectively.
In the pre-PCV10/13 period, 37 (29.6%) of the 125 isolates had allelic profiles that were indistinguishable from or closely related (SLVs or DLVs) to 10 international clones recognized by the Pneumococcal Molecular Epidemiology Network (PMEN; http:// www.pneumogen.net/pmen/). In the post-PCV10/13 period, 52 (39.7%) of the 131 isolates were related to nine PMEN international clones (P " 0.09) ( Table 2) .
Serotype switching events were detected within two lineages. ST724 was associated with serotypes 6B and 6C in the pre-and post-PCV10/13 periods, respectively. In turn, ST338 was associated with serotype 23F in the pre-PCV10/13 period and with serotypes 23A, 23B and 23F in the post-PCV10/13 period.
All isolates were susceptible to levofloxacin, rifampicin and vancomycin. Only three MDR isolates, two NT-ST2315 and one serotype 6C-ST812, were resistant to chloramphenicol. The highest non-susceptibility (intermediate plus resistant) frequencies were observed for trimethoprim/sulfamethoxazole: 77 (61.6%) among 125 isolates of the pre-PCV10/13 period, including 16 serotypes and NT isolates comprising 33 STs; and 53 (40.5%) among 131 isolates from the post-PCV10/13 period, including 14 serotypes and NT isolates of 32 STs. PNSP (MICs " 0.12-8 mg/L) were found in 30 (24%) of 125 and 51 (38.9%) of 131 pre-and post-PCV10/13 isolates (P " 0.01), encompassing 14 and 24 distinct STs from each period, respectively. PNSP were clustered into five and six CCs, with seven and eight singletons in the pre-and post-PCV10/13 periods, respectively. In the pre-PCV10/13 period, ST156/Spain In the pre-PCV10/13 period, erythromycin non-susceptibility was only observed in three (2.4%) isolates (two serotype 6A-ST1190 isolates and one serotype 10A-ST7023 isolate), with MICs ranging from 0.5 to 4 mg/L. In turn, 36 (27.5%) isolates comprising 15 different STs were resistant to erythromycin (MICs from 1.5 to .256 mg/L) in the post-PCV10/13 period, most commonly (15/36; 41.7%) MDR serotype 6C-CC386 (P , 0.01). 
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Erythromycin-resistant isolates were clustered into six CCs and five singletons in the post-PCV10/13 period and were associated with seven PMEN clones (Figure 1b) . Of note, clindamycin resistance was not observed in the pre-PCV10/13 period, but it was observed in 26 (19.8%) of 131 isolates belonging to 10 different STs in the post-PCV10/13 period (P , 0.01), always co-occurring with erythromycin resistance. Table 3 shows the distribution of STs according to penicillin, ceftriaxone and erythromycin MICs.
Resistance to tetracycline was observed in 13 (10.4%) isolates, belonging to seven different serotypes and STs, mainly (6/13; 46.2%) serotype 17F-ST739, in the pre-PCV10/13 period. In the post-PCV10/13 period, 5 (3.8%) isolates were intermediate to tetracycline and 32 (24.4%) isolates were resistant to tetracycline, comprising 11 serotypes and NT isolates, including six PMENrelated clones. Fifteen (40.5%) of these 37 isolates belonged to the MDR serotype 6C-CC386, including 1 ST8587 isolate and 14 ST386 isolates (P , 0.01).
Discussion
After 4 years of routine childhood PCV use, mostly PCV10, in a large metropolitan area of Rio de Janeiro state, Brazil, we observed that STs included among PCV10 serotypes were rarely found in the post-PCV10/13 period among pneumococcal strains colonizing children under 6 years old. However, PCV universal use did not result in lower antimicrobial drug resistance frequencies. Internationally disseminated clones recognized by the PMEN were mainly responsible for antimicrobial resistance. Higher resistance frequencies in the post-PCV10/13 period were primarily driven by the emergence of the MDR serotype 6C-CC386, a DLV of Poland 6B -20. High prevalence (44%) of PMEN clones causing severe pneumococcal diseases was also observed among patients in a cancer reference hospital in the same geographical area in Brazil between 2013 and 2014; 12 eight of these clones were found colonizing (6) 15B/C (6) 1262 (12) 15C (6) 15B/C (6) 156 (10) 14 (9) (4) 6A (5) 733 (5) e 19A (4), 19F (1) -1190 (5) 6A (2) 6A (3) 7082 (5) 16F (3) 16F (2) 558 (4) -
23B (1) 743 (4) 34 (1) 34 (3) 2315 (4) e NT (1) NT (3) 7093 (4) 15A (2) 15A/F (2) NT, non-typeable. Pre-PCV10/13 (n " 37) Post-PCV10/13 (n " 52) (15) ST62 (4) 11A (4) ST62 (9) Post-vaccination emergence of the MDR serotype 6C-CC386 in Brazil JAC children. These include ST156, ST180 and ST218 in the pre-PCV10/ 13 period, ST320 and ST558 in the post-PCV10/13 period and ST42, ST62 and ST338 in both periods. Similar findings were seen among IPD isolates in southern Brazil between 2007 and 2012. 13 CC724, associated with serogroup 6, was the most common (18.4%) CC in the pre-PCV10/13 period. Reports of this penicillinsusceptible clone causing disease in Brazil since 2000 are sporadic.
12-14 However, the ability of ST724 to undergo serotype switching (6B to 6C in the pre-and post-PCV10/13 periods, respectively) suggests its evolutionary adaptability to current prevention strategies.
In the post-PCV10/13 period, three CCs (386, 62 and 42) accounted for nearly one-third of the 131 isolates. All of them were closely related to PMEN clones.
Serotype 6C-CC386 was only found in the post-PCV10/13 period. This MDR lineage was responsible for more than half of the prevalence of clindamycin-, 42% of erythromycin-, 41% of tetracycline-and nearly 30% of penicillin-non-susceptible strains in this period. This lineage expressed high erythromycin MICs (.256 mg/L), the constitutive macrolide/lincosamide/streptogramin B (MLS B ) phenotype and carried the erm(B) gene.
14 Carriage and IPD isolates of serotype 6C emerged worldwide following PCV7 15, 16 and PCV10 [17] [18] [19] introduction. Interestingly, CC386 MDR isolates emerged as a cause of IPDs among adults in Spain 20 and carriage among children in Portugal. 21 We detected a clonal expansion of CC62, a DLV of Netherlands 8 -33. Six STs were found in the post-PCV10/13 period, including three new variants associated with capsular types 11A/D (ST11288, ST11370 and ST11372), 19A (ST1118) and 23B (ST6605). These findings indicate the genetic plasticity of this CC. Similarly, clonal expansion of CC62 was the main driver behind the increase in carriage of serotype 11A among children after PCV7 and PCV13 introduction in Sweden. 22 CC42, the third most common CC in the post-PCV10/13 period, is closely related to the Tennessee 23F -4 clone. This CC was associated with serotypes 23A and 23B in both periods. The number of isolates and clonal diversity within CC42, however, was much greater in the post-PCV10/13 period, with eight STs compared with only two in the pre-PCV10/13 period. Emergence of CC42-related lineages, such as ST439, has also been reported in Germany in the PCV13 era.
23
Serotype 19A is one of the most important replacement serotypes following PCV7 introduction associated with carriage and IPDs. Increasing prevalence of MDR serotype 19A-ST320, a DLV of Taiwan 19F -14, has been reported in other countries before and shortly after PCV13 introduction. [24] [25] [26] In the present study, the prevalence of serotype 19A was low in both sampling periods and, unlike what happened in countries where PCV7 was implemented, we believe that serotype 19A did not emerge in carriage because PCV10 may have offered cross-protection against this serotype, as previously suggested. 27 It is, however, noteworthy that four of the five serotype 19A isolates of the post-PCV10/13 period were identical or closely related to ST320, including two new SLVs (ST11290 and ST11292), which had the highest MICs of erythromycin, ceftriaxone and penicillin; they were exclusively found in private clinics. Since PCV13 coverage is low in Brazil, we believe that the successful persistence of these lineages in the country will be primarily driven by selective antimicrobial pressure.
As opposed to serotypes 6C and 19A, which appear to be declining in prevalence in countries where PCV13 is universally used, 28,29 the non-PCV13 serogroup 15 and serotype 35B have been emerging worldwide. 6, 17, 23, 24, 29 In our study, serogroup 15 was responsible for 8% and 18% of the isolates in the pre-and post-PCV10/13 periods, respectively, and several serogroup 15-associated clones reported here were observed among IPD cases in Brazil. 12, 13 Additionally, serotype 35B has been often associated with penicillin resistance 24, 29 and we detected four Penicillin MICs were higher among isolates recovered after PCV introduction; 80% of the 51 PNSP of the post-PCV10/13 period had MICs between 0.5 and 8.0 mg/L compared with one-third of the 30 isolates recovered before PCV10/13 introduction (P , 0.01). Previous studies conducted in Brazil have shown that serotype 14-ST156/ Spain 9V -3 was the major clone behind emergence of PNSP.
14, 30 The lack of detection of this clone after PCV introduction is noteworthy, suggesting the effectiveness of PCV in reducing its circulation.
There are several limitations in the present study. First, sampling in the pre-PCV10/13 period took place in four different locations, but most isolates were recovered from children who attended one public CCC (47%) or one public paediatric hospital (48%). In the post-PCV10/13 period, sampling was evenly done in one public and two private paediatric clinics. However, all isolates were recovered from children younger than 6 years, who possessed similar demographic and clinical characteristics. Secondly, there were only nine (7%) isolates (two of capsular type 15B/C and one each of 6C, 11A/D, 16F, 23A and 23F, as well as two NT isolates) in the post-PCV10/13 period recovered from children vaccinated with PCV13, making it difficult to evaluate PCV13's effect on clonal composition of the pneumococcal population. Finally, since we did not analyse isolates representative of all periods after PCV introduction, our study was not a trend analysis to evaluate changes over time, but a comparison of two cross-sectional analyses of similar populations in the same city before and after PCV10/13 implementation for routine use.
In conclusion, we observed a diverse genetic background among the pneumococcal population in the study area. Capsular switching events involving antimicrobial-susceptible and -resistant serogroups 6 and 23 were detected. Penicillin non-susceptibility was polyclonal in both sampling periods, but a large proportion of these isolates belonged to a few clones, predominantly serotype 14-ST156 and serotype 6C-CC386 in the pre-and post-PCV10/13 periods, respectively. Erythromycin resistance was observed among several genotypes after 4 years of PCV10 universal use, but the high frequency was largely due to the emergence and expansion of MDR serotype 6C-CC386. Expanding PCV13 use might reduce serotype 6C-associated genotypes due to cross-protection with serotype 6A, 24 although we have found one serotype 6C isolate colonizing one child who had received four doses of PCV13. Ongoing surveillance of the clonal composition of pneumococcal isolates is important to detect events selected by PCV universal use, such as serotype replacement, capsular switching and clonal expansion, and to identify factors other than PCV vaccination that drive the evolution of drug-resistant pneumococci.
